No profile data available.
Nuvectis Pharma, Inc. (NVCT) is a healthcare company in the additional cancer treatment drugs industry, based in Fort Lee, United States, with about 16 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$28.87 million. Its market capitalization was $689.44 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Nuvectis Pharma reported $0 in revenue for fiscal year 2025.
$689.44 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include ArriVent BioPharma, Inc. (AVBP), Candel Therapeutics, Inc. (CADL), Verastem, Inc. (VSTM), Aura Biosciences, Inc. (AURA).